Treatment of a Neonatal Peripheral Intravenous Infiltration/Extravasation (PIVIE) Injury With Hyaluronidase: A Case Report

Q3 Medicine
M. V. van Rens, Kevin Hugill, A. Francia, A. Abdelwahab, Krisha L. P. Garcia
{"title":"Treatment of a Neonatal Peripheral Intravenous Infiltration/Extravasation (PIVIE) Injury With Hyaluronidase: A Case Report","authors":"M. V. van Rens, Kevin Hugill, A. Francia, A. Abdelwahab, Krisha L. P. Garcia","doi":"10.2309/java-d-21-00010","DOIUrl":null,"url":null,"abstract":"\n \n \n \n \n Introduction: Intravenous therapy-related injury, its prevention, and treatment are ubiquitous topics of interest among neonatal clinicians and practitioners. This is due to the economic costs, reputational censure, and patents’ wellbeing concerns coupled with the possibility of potentially avoidable serious and life-long harm occurring in this vulnerable patient population.\n Case description: A term infant receiving a hypertonic dextrose infusion for the management of hypoglycemia developed a fulminating extravasation shortly after commencement of the infusion. This complication developed without notification of infusion pump pressure changes pertaining to a change in blood vessel compliance or early warning of infiltration by the optical sensor site monitoring technology (ivWatch®) in use. The injury was extensive and treated with a hyaluronidase/saline mix subcutaneously injected into the extravasation site using established techniques. Over a period of 2 weeks, the initially deep wound healed successfully without further incident, and the infant was discharged home without evident cosmetic scarring or functional effects.\n Conclusion: This article reports on a case of a term baby who postroutine insertion of a peripherally intravenous catheter showed an extreme reaction to extravasation of the administered intravenous fluids. We discuss the condition, our successful management with hyaluronidase, and the need to remain observationally vigilant of intravenous infusions despite the advances in infusion monitoring technology.\n","PeriodicalId":35321,"journal":{"name":"JAVA - Journal of the Association for Vascular Access","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAVA - Journal of the Association for Vascular Access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2309/java-d-21-00010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Intravenous therapy-related injury, its prevention, and treatment are ubiquitous topics of interest among neonatal clinicians and practitioners. This is due to the economic costs, reputational censure, and patents’ wellbeing concerns coupled with the possibility of potentially avoidable serious and life-long harm occurring in this vulnerable patient population. Case description: A term infant receiving a hypertonic dextrose infusion for the management of hypoglycemia developed a fulminating extravasation shortly after commencement of the infusion. This complication developed without notification of infusion pump pressure changes pertaining to a change in blood vessel compliance or early warning of infiltration by the optical sensor site monitoring technology (ivWatch®) in use. The injury was extensive and treated with a hyaluronidase/saline mix subcutaneously injected into the extravasation site using established techniques. Over a period of 2 weeks, the initially deep wound healed successfully without further incident, and the infant was discharged home without evident cosmetic scarring or functional effects. Conclusion: This article reports on a case of a term baby who postroutine insertion of a peripherally intravenous catheter showed an extreme reaction to extravasation of the administered intravenous fluids. We discuss the condition, our successful management with hyaluronidase, and the need to remain observationally vigilant of intravenous infusions despite the advances in infusion monitoring technology.
透明质酸酶治疗新生儿外周静脉浸润/外渗(PIVIE)损伤1例报告
引言:静脉注射治疗相关损伤、预防和治疗是新生儿临床医生和从业者普遍感兴趣的话题。这是由于经济成本、声誉谴责和专利的健康问题,再加上在这一弱势患者群体中可能发生可避免的严重和终身伤害。病例描述:一名接受高渗葡萄糖输注治疗低血糖症的足月儿在输注后不久出现暴发性外渗。这种并发症的发生没有通知与血管顺应性变化有关的输注泵压力变化,也没有使用光学传感器现场监测技术(ivWatch®)对浸润进行预警。损伤范围广泛,使用已建立的技术将透明质酸酶/生理盐水混合物皮下注射到外渗部位进行治疗。在2周的时间里,最初的深伤口成功愈合,没有发生进一步的事故,婴儿出院回家,没有明显的美容疤痕或功能影响。结论:本文报道了一例足月婴儿,在常规外周静脉导管插入后,对静脉输液外渗表现出极端反应。我们讨论了这种情况,我们使用透明质酸酶的成功管理,以及尽管输液监测技术取得了进步,但仍需要对静脉输液保持观察警惕。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAVA - Journal of the Association for Vascular Access
JAVA - Journal of the Association for Vascular Access Medicine-Medicine (miscellaneous)
CiteScore
1.10
自引率
0.00%
发文量
22
期刊介绍: The Association for Vascular Access (AVA) is an association of healthcare professionals founded in 1985 to promote the emerging vascular access specialty. Today, its multidisciplinary membership advances research, professional and public education to shape practice and enhance patient outcomes, and partners with the device manufacturing community to bring about evidence-based innovations in vascular access.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信